Company Profile
Regeneron Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- REGN
- Exchange:
- NASDAQ
- Sector:
- Antibody Drugs, Biopharma
- Location:
- United States
Stock performance
902.90 USD (-2.98%)
Close
Last updated: November 5, 2026
63.2B USD
Market cap
Why the stock is moving
As of Nov 5, 2026, REGN closed down 2.98% at $902.90. No new same-company headline was identified in the current news window.
Company overview
Integrated Biopharmaceutical Company
Regeneron Pharmaceuticals discovers, develops, manufactures and commercializes medicines across ophthalmology, immunology, oncology, rare disease, cardiovascular medicine and other areas. Its internal technology platforms support a large clinical portfolio and multiple global collaborations.
Retinal Disease Franchise
EYLEA and EYLEA HD are anti-VEGF therapies used in retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema. EYLEA HD offers extended dosing intervals and anchors Regeneron’s ophthalmology business.
Dupixent Collaboration
Dupixent is an IL-4 receptor alpha antibody developed globally with Sanofi across type 2 inflammatory diseases. Its indications span dermatologic, respiratory and allergic conditions, including recent expansions into pediatric chronic spontaneous urticaria and allergic fungal rhinosinusitis.
Oncology Pipeline
Regeneron commercializes the PD-1 antibody Libtayo and is developing fianlimab, a LAG-3 antibody, with cemiplimab in metastatic and adjuvant melanoma. The company’s oncology strategy combines proprietary antibodies across complementary immune pathways.
Rare-Disease Medicines
Otarmeni is an approved AAV gene therapy for OTOF-related severe-to-profound hearing loss. Garetosmab, an Activin A antibody, is under regulatory review for fibrodysplasia ossificans progressiva, while cemdisiran is an siRNA therapy submitted for myasthenia gravis.
Cardiovascular and Metabolic Programs
REGN7508 and REGN9933 are Factor XI antibodies in Phase 3 development for thrombosis prevention. Mibavademab is a leptin-receptor agonist antibody in Phase 3 testing for monogenic obesity.
Future catalysts
- FDA decision on cemdisiran for generalized myasthenia gravis in November 2026.
- Interim CIDEB RNAi data in MASLD at AASLD in November 2026 and initiation of a Phase 3 MASH/MASLD study in the fourth quarter of 2026.
- Phase 2 baloncibart results in postural orthostatic tachycardia syndrome in November 2026.
- FDA target action date for the resubmitted Ordspono BLA in diffuse large B-cell lymphoma in February 2027.
- FDA target action date for the alternative every-six-week Libtayo dosing regimen in March 2027.
- Initiation of a Phase 3 baloncibart study in postural orthostatic tachycardia syndrome in the first half of 2027, pending regulatory feedback.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals (REGN) most recently closed at 902.90 USD, a -2.98% move versus the previous session.
What is the market cap of Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals currently has a market capitalization of 63.2B USD on BioPharmSignal.
What does Regeneron Pharmaceuticals do?
Integrated Biopharmaceutical Company Regeneron Pharmaceuticals discovers, develops, manufactures and commercializes medicines across ophthalmology, immunology, oncology, rare disease, cardiovascular medicine and other areas. Its internal technology platforms support a large clinical portfolio and multiple global collaborations. Retinal Disease...
On which exchange is REGN stock listed?
Regeneron Pharmaceuticals (REGN) is associated with NASDAQ, United States, Antibody Drugs, Biopharma.
What is IL-4?
Dupixent Collaboration Dupixent is an IL-4 receptor alpha antibody developed globally with Sanofi across type 2 inflammatory diseases.
Which conditions is Regeneron Pharmaceuticals targeting with IL-4?
Regeneron Pharmaceuticals is associated with oncology, immunology, rare disease based on its company overview and current catalyst commentary.
How does Regeneron Pharmaceuticals describe recent progress with IL-4?
FDA decision on cemdisiran for generalized myasthenia gravis in November 2026. Interim CIDEB RNAi data in MASLD at AASLD in November 2026 and initiation of a Phase 3 MASH/MASLD study in the fourth quarter of 2026. Phase 2 baloncibart results in postural orthostatic tachycardia syndrome in November 2026. FDA target action date for the resubmitted Ordspono...
What is PD-1?
Oncology Pipeline Regeneron commercializes the PD-1 antibody Libtayo and is developing fianlimab, a LAG-3 antibody, with cemiplimab in metastatic and adjuvant melanoma.